Acute myocardial infarction is among the most studied applications of stem cell therapy. Over 20,000 clinical study subjects across 23C's research network have received cell therapy spanning cardiac, neurological, and autoimmune conditions, with acute myocardial infarction among the most frequent.
A heart attack (acute myocardial infarction) happens when blood supply to part of the heart is blocked, causing muscle tissue to die. Emergency intervention, stents, bypass surgery, thrombolytics, can restore blood flow, but the scarred muscle that remains does not regenerate on its own.
Scar tissue is not functional heart muscle. Over time, an infarcted heart works harder with less capacity, and the risk of progressive heart failure rises. Cell therapy is studied for its ability to support cardiac tissue repair, reduce fibrosis, and improve residual heart function — with early regenerative and recovery effects reported within the first 72 hours of treatment in documented cases.
The medical term for a heart attack, when blood supply to a region of the heart is blocked and muscle tissue dies from lack of oxygen. Emergency treatment focuses on restoring blood flow; cell therapy focuses on what happens afterward, repairing or limiting the lasting damage.
In the weeks and months after a heart attack, the body forms scar tissue where muscle was lost. This scar does not contract and reduces overall heart function. MSC therapy is studied for its potential to support residual muscle, reduce scarring, and improve cardiac output.
Untreated infarct damage progresses toward chronic heart failure over years. Patients experience fatigue, shortness of breath, and reduced exercise tolerance. Early cell therapy intervention may slow this trajectory and protect remaining cardiac function.
Cardiovascular disease often extends beyond the heart. For patients with poor circulation in the limbs, MSC therapy has been studied for vascular repair and improved blood flow, sometimes avoiding amputation in severe cases.
IV infusion of highly potent umbilical cord mesenchymal stem cells. Unlike bone marrow or adipose-derived cells, Wharton's Jelly MSCs have the lowest immunogenicity and the highest regenerative capacity, supporting cardiac tissue repair.
The best outcomes in cardiac cell therapy research are associated with treatment administered during the recovery window after the acute event, not during the emergency itself. Protocols are designed around each patient's cardiology timeline.
Cell therapy is coordinated with the patient's cardiology team. The focus is supporting the heart's remaining capacity, reducing systemic inflammation, and supporting broader cardiovascular health over the long term.
The following improvements have been reported by past patients. Results vary by individual, improvements cannot be guaranteed.
Stents and bypass address the blockage. Cell therapy addresses what the blockage left behind. Share your cardiology reports, recent echocardiogram, and current medications. Our medical team will coordinate with your cardiologist to assess how cell therapy may support your recovery.
Request a Case Review